Inside informationEnglish
OSE Immunotherapeutics Hosts KOL Webinar Post-ECCO on Lusvertikimab and the Future of IBD
The file is served by the AMF. We do not host a copy.
Document type
- Issuer
- Ose Immunotherapeutics
- Filed
- 06/03/2025, 18:00
- Document type
- Inside information
- AMF sub-type
- Informations privilégiées
- Language
- English
- AMF reference
- 112377_20250306